BALL Score for Relapsed/Refractory CLL

The BALL score predicts survival in relapsed/refractory CLL using β2‑microglobulin, anemia, LDH, and time from last therapy.

β2-microglobulin
< 5 mg/dl0≥ 5 mg/dL+1
Anemia
No0Yes+1
LDH
≤ upper limit of normal0> upper limit of normal+1
Last therapy (time from initiation)
≥ 24 months0< 24 months+1

Indicazioni d'uso

Identifies relapsed/refractory CLL patients at higher risk for early progression or death on ibrutinib-based therapy to guide prognosis and trial referral. Uses B2M, anemia, LDH, and time from last therapy to stratify risk; higher scores correlate with inferior survival in pooled analyses of ibrutinib-treated cohorts 1 [Level II evidence]. Also prognostic across other targeted regimens, supporting broader utility.

Approfondimenti e precauzioni

Identifies higher‑risk R/R CLL using β2‑microglobulin, anemia, LDH, and time since last therapy.

  • High scores = shorter PFS/OS, validated across real‑world cohorts.
  • Useful for prognostic stratification, not treatment selection.
  • Cautions: underestimates impact of TP53 aberrations, complex karyotype, and evolving resistance; prognosis varies with newer BTK/BCL2 inhibitors.
  • Should not replace genetic testing when choosing therapy.